Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs

Calquence(®) (crystalline acalabrutinib), a commercially marketed tyrosine kinase inhibitor (TKI), exhibits significantly reduced oral exposure when taken with acid-reducing agents (ARAs) due to the low solubility of the weakly basic drug at elevated gastric pH. These drug–drug interactions (DDIs) n...

Descripción completa

Detalles Bibliográficos
Autores principales: Mudie, Deanna M., Stewart, Aaron M., Rosales, Jesus A., Biswas, Nishant, Adam, Molly S., Smith, Adam, Craig, Christopher D., Morgen, Michael M., Vodak, David T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071435/
https://www.ncbi.nlm.nih.gov/pubmed/33921109
http://dx.doi.org/10.3390/pharmaceutics13040557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071435/
https://www.ncbi.nlm.nih.gov/pubmed/33921109
http://dx.doi.org/10.3390/pharmaceutics13040557

Ejemplares similares